Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB)

Next Previous
Trial Profile

VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer; Orbital tumours
  • Focus Therapeutic Use
  • Acronyms VISORB

Most Recent Events

  • 01 Jul 2021 Primary endpoint (The number of patients with a score of 21 or greater by the Visual Assessment Weighted Score (VAWS)) has been met, according to the results published in the Oncologist.
  • 01 Jul 2021 Results published in the Oncologist
  • 01 Jul 2021 Status changed from discontinued to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top